Background: Neuromyelitis optica spectrum disorders (NMOSD) are a spectrum of neuroinflammatory disorders associated with autoimmune antibodies against aquaporin-4 (AQP4). Accumulating evidence suggests that inflammation is involved in NMOSD pathogenesis. Resolution of inflammation, which is a highly regulated process mediated by specialized pro-resolving lipid mediators (SPMs) is important to prevent over-responsive inflammation. Deficiency in resolution of inflammation may lead to or accelerates inflammatory diseases. However, whether resolution of inflammation is impaired in NMOSD is not known. The objective of this study was to analyze the levels of SPMs in the serum and cerebrospinal fluid (CSF) of NMOSD patients, and to explore the roles of SPMs in clinical features of NMOSD.
Methods: Thirty-five patients with NMOSD, 34 patients with multiple sclerosis, and 36 patients with non-inflammatory neurological diseases were enrolled in this study. Pro-resolving mediators including Annexin A1 (ANXA1) and resolvin D1 (RvD1), as well as pro-inflammatory lipid mediator leukotriene B4 (LTB4) levels were analyzed by enzyme-linked immunosorbent assay. Pro- and anti-inflammatory cytokines as well as chemokine levels were analyzed using cytometric beads array (CBA).
Results: Our results showed RvD1 levels were significantly decreased, whereas LTB4 levels were significantly increased in the CSF of NMOSD patients. AQP4-IgG titer was negatively correlated with RvD1 levels in the CSF of NMOSD patients.
Conclusions: Decreased RvD1 levels indicate impaired resolution of inflammation in NMOSD patients. AQP4-IgG may contribute to increased inflammation and lead to unresolved inflammation in NMOSD.
Keywords: AA; AEs; ANXA1; AQP4; AQP4-IgG; Annexin A1; BBB; CBA; CNS; CSF; CXCL13; Cytometric Beads Array; DHA docosahexanoic acid; EDSS; ELISA; EPA; Expanded Disability Status Scale; Inflammation; LETM; LMs; LTB4; LXA(4); MS; NMO; NMO spectrum disorders ONNDs, non-inflammatory neurological diseases; NMOSDs; Neuromyelitis optica spectrum disorders; Resolution; Resolvin D1; RvD1; SPMs; adverse effects; annexin A1; aquaporin-4; arachidonic acid; blood brain barrier; central nervous system; cerebrospinal fluid; chemokine (C-X-C motif) ligand 13; eicosapentanoic acid; enzyme-linked immunosorbent assay; leukotriene B4; lipid mediators; lipoxin A4; longitudinally extensive myelitis; multiple sclerosis; neuromyelitis optica; resolvin D1; specialized pro-resolving lipid mediators.
Copyright © 2018. Published by Elsevier B.V.